PTC
TARS icon

Petrus Trust Company’s Tarsus Pharmaceuticals TARS Stock Holding History

Petrus Trust Company’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7,061
Closed -$286K – 499
2025
Q2 		$286K Buy
+7,061
New +$318K 0.03% 337

Other funds holding TARS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Petrus Trust Company's TARS Position: Q3 2025 in Review

Petrus Trust Company sold out of Tarsus Pharmaceuticals (TARS) in Q3 2025, closing a stake of 7,061 shares — an estimated $286K sold.

Petrus Trust Company first reported a position in TARS in Q2 2025 and held it in 1 quarter. The position peaked at $286K in Q2 2025. 220 funds tracked by Wall St. Rank hold TARS as of Q3 2025.

  • Petrus Trust Company reported no remaining Tarsus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Petrus Trust Company sold 7,061 Tarsus Pharmaceuticals shares in Q3 2025, an estimated $286K.
  • Petrus Trust Company first reported a position in Tarsus Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Petrus Trust Company's Tarsus Pharmaceuticals position peaked at $286K in Q2 2025.
  • 220 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q3 2025.

Based on Petrus Trust Company's 13F filing for Q3 2025, filed 14 Nov 2025.